Add to ORKG© 2015 Korkola et al.We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2+ breast cancers. We accomplished this by measuring cellular and molecular responses to lapatini
So-called “targeted therapeutics”, agents with tumour-selective action, promise to revolutionise tre...
Abstract Background Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldw...
Linking the molecular aberrations of cancer to drug responses could guide treatment choice and ident...
We report here on experimental and theoretical efforts to determine how best to combine drugs that i...
<div><p>We report here on experimental and theoretical efforts to determine how best to combine drug...
© 2015 Korkola et al. We report here on experimental and theoretical efforts to determine how best t...
<p><b>A</b>. Western blots of SKBR3 cells transduced with retroviruses encoding either PIK3CA<sup><i...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
HER2-targeted therapies have greatly improved the outcome for patients with HER2-positive breast can...
<p><b>A</b>. A simplified kinetic model for AKT pathway dynamics. Measured protein species (green; y...
Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, ...
Breast cancers with HER2 amplification represent 20-25% of breast cancer cases and are frequently re...
The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly targ...
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of al...
Background: Approximately 15%-20% of all diagnosed breast cancers are characterized by amplified and...
So-called “targeted therapeutics”, agents with tumour-selective action, promise to revolutionise tre...
Abstract Background Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldw...
Linking the molecular aberrations of cancer to drug responses could guide treatment choice and ident...
We report here on experimental and theoretical efforts to determine how best to combine drugs that i...
<div><p>We report here on experimental and theoretical efforts to determine how best to combine drug...
© 2015 Korkola et al. We report here on experimental and theoretical efforts to determine how best t...
<p><b>A</b>. Western blots of SKBR3 cells transduced with retroviruses encoding either PIK3CA<sup><i...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
HER2-targeted therapies have greatly improved the outcome for patients with HER2-positive breast can...
<p><b>A</b>. A simplified kinetic model for AKT pathway dynamics. Measured protein species (green; y...
Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, ...
Breast cancers with HER2 amplification represent 20-25% of breast cancer cases and are frequently re...
The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly targ...
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of al...
Background: Approximately 15%-20% of all diagnosed breast cancers are characterized by amplified and...
So-called “targeted therapeutics”, agents with tumour-selective action, promise to revolutionise tre...
Abstract Background Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldw...
Linking the molecular aberrations of cancer to drug responses could guide treatment choice and ident...